4//SEC Filing
Redmile Group, LLC 4
Accession 0001104659-25-083134
CIK 0001680367other
Filed
Aug 25, 8:00 PM ET
Accepted
Aug 26, 5:00 PM ET
Size
11.8 KB
Accession
0001104659-25-083134
Insider Transaction Report
Form 4
Redmile Group, LLC
Director10% Owner
Transactions
- Award
Common Warrants to Purchase Common Stock
2025-08-25+4,097,730→ 4,097,730 total(indirect: See Footnotes)Exercise: $1.08→ Common Stock (4,097,730 underlying) - Award
Pre-Funded Warrants to Purchase Common Stock
2025-08-25+4,097,730→ 7,198,553 total(indirect: See Footnotes)Exercise: $0.00→ Common Stock (4,097,730 underlying)
Green Jeremy
Director10% Owner
Transactions
- Award
Pre-Funded Warrants to Purchase Common Stock
2025-08-25+4,097,730→ 7,198,553 total(indirect: See Footnotes)Exercise: $0.00→ Common Stock (4,097,730 underlying) - Award
Common Warrants to Purchase Common Stock
2025-08-25+4,097,730→ 4,097,730 total(indirect: See Footnotes)Exercise: $1.08→ Common Stock (4,097,730 underlying)
Footnotes (4)
- [F1]On August 25, 2025 (the "Closing Date"), pursuant to the terms of that certain securities purchase agreement, dated as of August 4, 2025 (the "Purchase Agreement") and following the satisfaction of certain material conditions set forth therein, the Issuer issued and sold to certain institutional investors in a private placement, including certain private investment vehicles managed by Redmile Group, LLC (the "Redmile Clients"), pre-funded warrants (the "Pre-Funded Warrants") to purchase shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock"), accompanied by warrants (the "Common Warrants") to purchase an equal number of shares of Common Stock (or, in lieu thereof, Pre-Funded Warrants to purchase up to the same number of shares), at a combined purchase price for both securities of $0.8676.
- [F2]The Pre-Funded Warrants and Common Warrants are exercisable by the holder at any time on or after the Closing Date, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants do not have an expiration date. The Common Warrants will expire 30 days after a public announcement of the data from the Issuer's Phase 1 clinical trial for SL-325 in healthy volunteers and the design of its Phase 2 clinical trial.
- [F3]The reported securities are directly owned by the Redmile Clients, and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as the investment manager of the Redmile Clients.
- [F4]The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Documents
Issuer
Shattuck Labs, Inc.
CIK 0001680367
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001425738
Filing Metadata
- Form type
- 4
- Filed
- Aug 25, 8:00 PM ET
- Accepted
- Aug 26, 5:00 PM ET
- Size
- 11.8 KB